Dual antiplatelet therapy dilemmas: Duration and choice of antiplatelets in acute coronary syndromes topical collection on management of acute coronary syndromes

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Dual antiplatelet therapy (DAPT) is a key component of therapy for acute coronary syndromes managed with and without percutaneous coronary intervention. Recent advances have given patients a wider variety of therapeutic options including the use of combinations of agents, dosing strategies, and durations of therapy. The optimal regimen minimizes thrombotic risk without increasing the risk of bleeding. Choosing the best therapy for each patient is an individualized dilemma that requires new, evidence-based tools to support regimen decision-making.

Original languageEnglish
Article number405
JournalCurrent Cardiology Reports
Volume15
Issue number10
DOIs
StatePublished - Oct 2013

Keywords

  • Acute coronary syndromes
  • Bleeding
  • Clinical prediction tool
  • Clopidogrel
  • Cost-effectiveness
  • Dual antiplatelet therapy
  • Ischemia
  • Platelet function testing
  • Prasugrel
  • Therapeutic window
  • Ticagrelor

Fingerprint

Dive into the research topics of 'Dual antiplatelet therapy dilemmas: Duration and choice of antiplatelets in acute coronary syndromes topical collection on management of acute coronary syndromes'. Together they form a unique fingerprint.

Cite this